Introduction
The class II alleles defined serologically as HLA-DR3 and DR4 are potent genetic determinants of susceptibility to type 1 diabetes mellitus (T1DM). 1 Among Caucasians, HLA-DR3 occurs most commonly on a single MHC class II haplotype HLA-DRB1*0301, DQA1*0501, DQB1*0201. This is usually carried as part of the 8.1 ancestral haplotype (AH; HLA-A1,B8,DR3,DQ2) in northern Europeans or on the 18.2AH (HLA-A30, B18, DR3, DQ2) in Southern Europeans. In contrast, several subtypes of HLA-DR4 are common and have divergent effects on T1DM. T1DM susceptibility has been associated with HLA-DRB1*0401, -DRB1*0402 and -DRB1*0405 alleles in several Caucasian cohorts. Conversely, HLA-DRB1*0403, and in some studies -DRB1*0404, marked resistance. [2] [3] [4] [5] Strong linkage disequilibrium between HLA-DR and -DQ complicates identification of critical class II alleles.
One possibility is that HLA-DQB1*0302 may confer susceptibility, while HLA-DR4 subtypes overlay this with varying degrees of resistance. 3 Alternatively, HLA-DR and -DQ alleles may both influence diabetogenesis, 4 possibly via trans-encoded heterodimers of -DQ proteins from some haplotypes, 1 or HLA-DRB1 may be the critical gene. 2 In addition to HLA class II alleles, other MHC genes are implicated in T1DM susceptibility. For example, the telomeric end of the central MHC on the 8.1AH, marked by haplotypic alleles of TNFA, BAT1 and HLA-B, was more frequently carried by T1DM patients than controls when both were preselected for carriage of HLA-DR3. Thus, the TNF region may amplify the diabetogenic effect of HLA-DR3,DQ2. 6 A similar effect has been identified in the Belgian Diabetes Cohort 7 and in Sardinian patients where HLA-DR3,DQ2 is more common as part of the 18.2AH. 8 Equivalent studies of HLA-DR4 are more complex, as the subtypes of HLA-DRB1*04 associated with susceptibility or dominant protection occur in several common ancestral haplotypes, which recombine more frequently than the 8.1AH. The 62.1AH (HLA-A2,B62,DRB1*0401,DQB1*0302) is common in Caucasian populations and associates with susceptibility to T1DM. 9 However, no studies have addressed whether the HLA class II alleles are solely responsible for this association or whether a polymorphism within an immune-related gene elsewhere in the MHC confers additional risk.
The West Australian population is largely Caucasian, reflecting recent migration from all parts of Europe. Here, we show that the HLA-DRB1*04 subtypes associated with susceptibility elsewhere have similar effects in Western Australian T1DM patients. We select haplotypic markers in the C4B and IKBL (NFKBIL1) genes and use them in a recombinant mapping analysis of the 62.1AH in T1DM and control subjects to evaluate the contribution of the central MHC.
Results

HLA-DR frequencies in T1DM patients and controls
As many diabetics in the cohort were typed before DNAbased genotyping was introduced in Western Australia, subtypes were degraded to the equivalent serological alleles to obtain the largest possible sample size. The distribution of serologically defined HLA-DR alleles was similar in childhood-onset type 1 diabetes (COD; o16 years at diagnosis) and adult-onset type 1 diabetes (AOD; X16 years at diagnosis). Significant differences between patients and controls are summarized in Table 1 . The frequency of HLA-DR2 was decreased in COD and AOD, while the frequencies of HLA-DR3 and HLA-DR4 were increased. The frequency of HLA-DR1 was decreased in AOD only (11.7 vs 21.0%, p ¼ 0.002, odds ratio (OR) ¼ 0.5). These results are consistent with previous studies. 9, 10 Eight different DRB1*04 subtypes were detected (Table 1) . HLA-DRB1*0401 and DRB1*0405 were significantly more common in patients. HLA-DRB1*0402 and HLA-DRB1*0403 were marginally associated with susceptibility and resistance (respectively), but were rare, so most differences were not significant. The distribution of HLA-DRB1*04 subtypes was similar in COD and AOD (P40.05).
In Caucasians, HLA-DRB1*0401 occurs predominantly on the 44.1AH (HLA-A2,B44,DRB1*0401,DQB1*0301) and 62.1AH (HLA-A2,B62,DRB1*0401,DQB1*0302). While HLA-DRB1*0405 is less common in most populations, linkage disequilibrium with HLA-B49 has been described.
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HLA-B alleles in T1DM patients and controls preselected for HLA-DR4 Statistically significant differences in carriage of HLA-B alleles in individuals carrying HLA-DR4 are summarized in Table 2 . The upper panel was based on broad serological typing to obtain the largest possible sample size. The frequencies of HLA-B5, HLA-B17 and HLA-B35 were lower in patients than controls, while the frequencies of HLA-B8 and HLA-B15 were higher in the patient groups. HLA-B12 (B44 and B45) was less common in HLA-DR4 þ COD than controls, but this was marginal with AOD.
Haplotypes containing HLA-B15 and HLA-B12 were investigated further. Among Western Australian bone Percentage of the total number of individuals with each allele (n).
marrow donors (BMD) with alleles corresponding to the serological HLA-B15 allele, 82% carried HLA-B62, 8% carried HLA-B63 and 10% carried HLA-B71, B72 or B75. This meant that alleles recorded as HLA-B15 could not be assumed to be B62 and the analysis was continued using the serological allele HLA-B15. A similar calculation established that 82% of BMD typed as HLA-B12 carried HLA-B44. However, HLA-B44 was reported in all samples that had high-resolution HLA class II typing and was used in subsequent analyses. Carriage of the serological HLA alleles characteristic of the 62.1AH (HLA-B15 with or without HLA-A2) was increased in patients stratified for the presence of HLA-DR4. Increased carriage of HLA-B15 was confirmed in patients with high-resolution HLA class II typing preselected for HLA-DRB1*0401 (Table 2 , lower panel). The results that suggest HLA-B15 or MHC alleles of the 62.1AH confer additional susceptibility to diabetes in individuals who carry HLA-DRB1*0401. Carriage of HLA-A2 conferred no greater risk than was seen with HLA-B15.
An analysis of patients and controls preselected for carriage of HLA-DRB1*0401 confirmed a negative association with HLA-B44, as seen with HLA-B12 and -DR4 (Table 2) .
Does the telomeric portion of the MHC influence T1DM?
A polymorphism defining the complement C4B3 allele was identified by DNA sequencing of EBV-transformed HLA-homozygous cell lines from the 10th International Histocompatibility Workshop (10IHW). Within this panel, C4B3 was only found in cell lines carrying the 62.1AH. Available high-resolution class II typing showed 100% (54/54) of COD, 96% of AOD (23/24) and 100% of BMDR controls (8/8) with C4B3 carried HLA-DRB1*0401 and HLA-DQB1*0302. Hence, the 62.1AH is conserved between HLA-DRB1 and C4B in patients and controls, in the same way as it is between DRB1 and DQB1. The C4B3 allele was more common in COD (18.6 vs 2.7%, Po0.0001, OR ¼ 8.3) and AOD (15.2 vs 2.7%, Po0.0001, OR ¼ 6.5) patients than controls, reflecting its haplospecific carriage on the 62.1AH.
A synonymous substitution at position þ 446 in exon 3 of the IKBL gene was identified by sequencing cDNA from 10IHW EBV-transformed cell lines, 12 and established as a haplotypic marker of the 62.1AH and the 35.2AH (HLA-A3,B35,DRB1*0101,DQB1*0501). 13 Here carriage of IKBL þ 446*T was similar in patients and controls (17.7% of COD, 14.3% of AOD vs 14.1% of controls). This suggests that many controls carry IKBL þ 446 without the HLA class II alleles of the 62.1 AH, possibly with HLA-B35 and/or DR1, which were negatively associated with T1DM in most comparisons (eg Table 2 ). Our analyses assumed that IKBL þ 446*T carried with HLA-DRB1*0401 marked the telomeric portion of the 62.1AH.
An additional local control cohort (n ¼ 190) was screened to facilitate further analysis of the 62.1AH. This yielded 31 HLA-DRB1*0401 donors, of whom two carried C4B3. This frequency is slightly lower than in the BMD cohort (2/31 vs 8/54, P ¼ 0.2). However, the two cohorts are derived from the same population, so the data were pooled (see Table 3 ). Carriage of C4B3 was (Table 3) . However, the OR for all comparisons involving carriage of the telomeric markers were greater than one and carriage of C4B3 without other markers of the 62.1AH (after preselection for HLA-DRB1*0401) was less common in patients. Similar results were obtained when the AOD and COD cohorts were combined. The differences may become significant when DNA from a larger control cohort becomes available, allowing mapping of genes in the telomeric portion of the 62.1AH that confer additional risk of T1DM.
HLA-DRB1*0405 haplotypes An equivalent approach was adopted to identify central MHC alleles carried in linkage disequilibrium with HLA-DRB1*0405 that may affect diabetes ( Table 1) . As HLA-DRB1*0405 is rare in our population, a BMD database (n ¼ 2006) was screened to identify 31 individuals with HLA-DRB1*0405. The most common HLA-B allele in T1DM patients with HLA-DRB1*0405 was HLA-B8 (11/34 samples), but 10 of these 11 individuals also carried HLA-DR3 suggesting carriage of the 8.1AH. The other allele observed commonly was HLA-B49, as noted previously. 11 There was a two-fold increase in carriage of HLA-B49 among T1DM patients relative to BMD when both were preselected for HLA-DRB1*0405 (9/34 (26%) vs 4/31 (12%), P ¼ 0.146), suggesting an effect of central MHC or class I alleles. This requires verification in a population where these alleles are more common.
Discussion
T1DM susceptibility has been associated with HLA-DRB1*0401, DRB1*0402 and DRB1*0405 alleles, while HLA-DRB1*0403 and in some studies *0404 marked resistance. [2] [3] [4] [5] Here we compared the frequency of HLA-DR4 alleles in West Australian T1DM patients divided into COD and AOD groups (age at diagnosis o16 years for COD and X16 years for AOD) and control subjects. HLA-DRB1*0401 and -DRB1*0405 were significantly more common in COD and AOD than in controls. We did not observe any major differences between AOD and COD, so the effect of MHC genes on diabetes appears to be independent of age of onset.
The identification of haplotypic markers is critical to the mapping of genes affecting disease. Newton et al 14 defined a series of TNF haplotypes to map MHC genes affecting rheumatoid arthritis, but could not distinguish haplotypes containing HLA-DRB1*0401 and -DRB1*0404. We have used 19 SNP spanning the TNF cluster (including IKBL þ 446) to define 17 haplotypes describing 90% of the control population. 13 Haplotypes containing HLA-DRB1*0401 and -DRB1*0404 were distinguished by several alleles including IKBL þ 446.
The 62.1AH is more frequent in T1DM patients than other haplotypes that carry HLA-DRB1*04 alleles. 9 Here in the presence of HLA-DRB1*0401, B15(62) was associated with susceptibility to diabetes, while HLA-B44 was more frequently carried with HLA-DRB1*0401 in controls. This suggests an interactive effect between HLA-DRB1 and linked genes in the MHC. It is often assumed that the gene enhancing the effect of HLA-DRB1*0401 is an HLA-DQ allele (in this case, HLA-DQ*0302) that is not shared with the 44.1AH (carrying HLA-DQ1*0301). However, this model has not explained why HLA-DRB1*0404 is not consistently associated with T1DM 3 (Table 1) , since this allele invariably occurs with DQB1*0302. Undlien et al 3 suggested that DRB1*0404 confers resistance that counteracts the diabetogenic effect of DQB1*0302, but did not provide a mechanism or investigate central MHC alleles as an alternative explanation for their findings. HLA-DRB1*0404 haplotypes have not been defined precisely, but a diabetogenic gene was mapped between TNF and HLA-B in patients from Finland stratified for carriage of HLA-DRB1*0404/*0301. The allelic distribution suggested that this did not lie on a conserved DRB1*0301 haplotype. 15 Here we showed that carriage of C4B3 and HLA-B15 significantly enhanced the risk of diabetes in carriers of HLA-DRB1*0401; (Tables 1 and 3 ). While we did not eliminate a role for HLA-DQB1*0302, a gene in the central MHC would explain our data. A central MHC effect contributing to susceptibility to T1DM has been described in HLA-DRB1*0404 patients 14 and HLA-DRB1*0301 patients. [6] [7] [8] Here IKBL þ 446*T and HLA-A2,B15 were used as haplotypic markers to identify an interactive effect between the class II alleles and the telomeric portion of the 62.1AH. Unfortunately, we had DNA an insufficient numbers of controls carrying HLA-DRB1*0401 (n ¼ 10) to obtain significant associations. However, carriage of all markers of the telomeric portion of the 62.1AH marginally increased the risk of diabetes in donors preselected for HLA-DRB1*0401. This was observed in donors positive for C4B3 where the high frequency of carriage of IKBL þ 446*T and HLA-B15 is consistent with a conserved haplotype. It was also evident without C4B3, in donors apparently carrying IKBL þ 446*T and HLA-B15 in trans with HLA-DRB1*0401 or as a result of a double recombination. Larger numbers of these recombinant donors would provide an accurate means of mapping the centromeric boundary from a central MHC gene affecting diabetes. IKBL þ 446 is a suitable marker for this purpose. 12, 13 Additional markers may be required to map the telomeric end, as HLA-A2 is common to several haplotypes, but this analysis can include donors carrying C4B3.
Candidate genes in the region implicated here include MICA and MICB. These encode stress-inducible class Irelated glycoproteins expressed on epithelial, endothelial and fibroblast-derived cells, but not lymphocytes. MIC proteins are ligands for the NKG2D protein expressed on natural killer cells and gdT cells. Nonsynonymous polymorphisms have been described on the edge of the peptide-binding groove in the a2 extracellular domain, in positions likely to affect interactions with NKG2D 16, 17 and in the transmembrane region. MICA transmembrane allele 5 may affect T1DM. 18 However, no known alleles are unique to haplotypes associated with T1DM. MICA transmembrane allele 5 does not correlate with T1DM in our cohort with or without stratification for HLA-DR3 or -DR4. 19 An interesting candidate gene is BAT1 (UAP56) telomeric of IKBL. BAT1 is a member of the 'DEAD-box' gene family encoding RNA helicases/RNA-dependent ATPases, related to the eIF-4A eucaryotic translation initiation factors. We generated Jurkat, U937 and THP1 cells expressing antisense BAT1 mRNA to demonstrate an immunoregulatory role for BAT1. 20 After mitogenic stimulation, antisense transfectants produced higher levels of TNF, IL-1 and IL-6 than cells carrying the vector alone. This suggests BAT1 down regulates production of acute-phase cytokines. There are several ways in which this could promote T1DM. Chronic immune activation leading to immunological senescence has been associated with shortening of the telomeres, notably in CD57 þ CD8 þ T cells. Shortened telomeres have been reported in cells from HLA-DRB1*04 controls and patients with rheumatoid arthritis, 21 and the generation of CD57 þ CD8 þ T-cells is promoted by TNFa.
22
In conclusion, the contributions of different MHC class II alleles to susceptibility and resistance to T1DM has been debated extensively. Here we use haplotypic markers to show that a gene in the central MHC could explain the differential effects of HLA-DR4 subtypes on T1DM. Our data do not suggest that the central MHC effect replaces that of HLA class II, but it may exacerbate or reduce ongoing immunopathology via regulation of TNFa.
Materials and methods
Patients and controls
Western Australian patients with type 1 diabetes (n ¼ 595) treated at Royal Perth Hospital (n ¼ 304) and Princess Margaret Hospital (n ¼ 291) were studied. The hospitals are located close together and draw from a similar population demographic. The combined cohort comprised 355 COD (o16 years at diagnosis; male:female ¼ 1.1; age at diagnosis ¼ 9.274.1 years) and 240 AOD (X16 years at diagnosis; male:female ¼ 1.8; age at diagnosis ¼ 29.7710.7 years). To confirm a diagnosis of T1DM, we checked that individuals who were X16 years at diagnosis had glutamic decarboxylase autoantibodies (at least 5 U/ml) and/or islet-cell autoantibodies (at least 1 U/ml) at some time during their disease. An experienced consultant reviewed the 25 patients who had been negative for these antibodies, since our database was instigated in 1997 and determined that they had a clinical presentation consistent with type 1 diabetes (ie stable insulin dependency, a lean body shape, a family history of diabetes and/or ketoacidosis). The control group comprised 491 random individuals from the West Australian Bone Marrow Donor (BMD) Registry from whom DNA was available. For the analysis described in Table 3 , 190 individuals from the Busselton Survey were added to this group. They are considered to represent an equivalent population demographic. Appropriate institutional ethics committees approved this study.
HLA typing HLA class I and II alleles were initially assigned serologically using standardized microcytotoxicity assays.
23 DNA-based HLA class II typing, 24 able to define HLA-DRB1*04 subtypes, was performed for 294 COD, 188 AOD and 486 controls.
C4B genotyping
Genotyping for the T/A substitution at the first base of codon 695 in exon 17 of the C4B locus (nucleotide 5129, GenBank U24578) was performed by PCR-SSP (SSP: sequence-specific primers). The A allele is specific to the C4B3 isoform. The product was amplified using C4B3 forward GACACGTCTGCCCATGATGAG and reverse ACCGTTCTGCCTTTCCAAG primers and included human growth hormone (HGH) primers as an internal control. Reaction mixes contained 100 ng genomic DNA, 2.5 mM MgCl 2 , 0.2 mM each dNTP, 0.5 pM each C4B3 primer, 0.25 pM each HGH primer and 1 U platinum Taq DNA polymerase (Invitrogen, USA) in 20 ml. Amplification was performed in a GeneAmp PCR System 9700 (Applied Biosystems, USA). Cycling conditions were 961C for 6 min, followed by eight cycles of 961C for 30 s, 701C for 30 s, 721C for 2 min, followed by 10 cycles of [961C for 30 s, 651C for 30 s, 721C for 2 min, followed by 17 cycles of 961C for 30 s, 551C for 30 s, 721C for 2 mins, with a final extension phase at 721C for 10 min. Samples were assessed as being positive for C4B3 when a 205 bp band was visible. Samples lacking C4B3 only had the 439 bp HGH control band. Genotype standards and a negative (water) control were included in all assays.
IKBL genotyping
Amplifluor genotyping for IKBL þ 446 alleles was performed at Centre Nationale de Genotypage (Evry, Paris) using automated high-throughput methods, as described previously. 25 Liquid handling was performed robotically in 384-well plates. The reaction mix included a common reverse primer GGGTCTCCCCATCCTTATTCTTT and two forward SSP, AAGCCGCTGTCCCTCC (green) and GCTAAGCCGCTGTCCCTCT (red), each with a tail complementary to an Amplifluor UniPrimer. Reaction mixes contained 5 ng genomic DNA. Genotype standards and water controls were included in each assay. Amplifluor reactions were performed in an H 2 OBIT thermal cycler (ABgene, UK). Cycling conditions were 941C for 4 min, followed by 20 cycles of 941C for 10 s, 551C for 5 s, 721C for 10 s, followed by 22 cycles of 941C for 10 s, 551C for 30 s, 721C for 40 s, with a final extension phase at 721C for 60 s. Fluorescence was detected using an ABI Prism 7900HT (Applied Biosystems, USA) and used to assign genotypes.
Statistical analysis
Differences in genotype and allele frequencies were assessed by Fisher's exact test and presented with OR and 95% confidence intervals (95% CI). All P-values o0.05 were considered statistically significant. 
